The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry
Novonesis has revealed plans to expand its facility in Patalganga, India, and build ‘one of the world’s most advanced’ enzyme production plants.
Supported by a €600 million investment, the facility will increase the company’s production capacity to meet rising global demand for its bio-solutions and strengthen its international supply network.
The facility is expected to be fully operational in 2030 and is described as a milestone in the company’s growth strategy. It will produce enzymes for the food and beverage industry, as well as other industries including biofuels and household care.
Novonesis’ newly expanded plant will bring it closer to customers across the Middle East, India, and Africa, markets that the company said it expects to see faster growth in than developed markets in the coming years.
Patalganga is part of a series of investments Novonesis has made to strengthen its global production setup and serve customers more effectively. Facilities in Rayong, Thailand; Franklinton, North Carolina; Taicang, China; Araucaria, Brazil; and West Allis, Wisconsin, have also been expanded as part of this.
Freshwater recycling will reduce the amount of water used at the site, while integrated heat pumps will lower the energy required for operations. Novonesis said these measures will ‘put the facility on a path toward lower Scope 1 and 2 emissions’.
Anders Lund, chief operating officer at Novonesis, said: “As demand for biosolutions continues to grow across industries and regions, expanding our global production capacity is a priority”.
“The Patalganga expansion will strengthen our scale, operational resilience, efficiency, and supply flexibility. Just as importantly, it brings us closer to customers in key growth markets, enabling us to meet their expectations and deliver on our long-term growth targets.”
Novonesis was established following the merger of Danish biotech players Novozymes and Chr. Hansen, completed in 2024. The company now has a workforce of 11,000 people worldwide, specialising in microbial science, fermentation and enzyme innovation.
